Literature DB >> 35922612

HBV Reactivation After Bariatric Surgery for HBV-Infected Obese Patients.

Chi-Ming Tai1,2, Hung-Pin Tu3, Jau-Chung Hwang4, Ming-Lun Yeh5,6, Chung-Feng Huang5,6, Ming-Lung Yu7,8,9.   

Abstract

BACKGROUND: The association between non-alcoholic fatty liver disease and hepatitis B virus (HBV) infection is inconclusive. The aim of this study was to investigate the viral dynamic of HBV and its association with change of body mass index (BMI), aspartate transaminase (AST), and alanine transaminase (ALT) levels after bariatric surgery.
METHODS: Patients who underwent bariatric surgery between June 2011 and May 2014 were selected in this retrospective study. BMI, AST, ALT, and HBV DNA levels were calculated pre-operatively and at 1st, 3rd, and 6th postoperative months.
RESULTS: Two hundred and seventy-nine patients including 34 (12.2%) HBsAg-positive and 245 (87.8%) HBsAg-negative patients were enrolled. Eighteen HBsAg-positive and HBeAg-negative patients were matched with 36 HBsAg-negative patients. A significant decrease in BMI was found since 1st postoperative month in both groups. AST and ALT increased at 1st postoperative month, but decreased at 3rd and 6th postoperative months in both groups. However, a significant increase in HBV DNA level was observed in HBeAg-negative patients since 1st postoperative month with the highest peak at 3rd postoperative month. HBV reactivation occurred in 4 out of 17 (23.5%) patients, 8 out of 16 (50.0%) patients, and 4 out of 12 (33.3%) patients at 1st, 3rd, and 6th postoperative months, respectively. The change of HBV DNA was not associated with change of BMI, AST, or ALT after bariatric surgery.
CONCLUSION: Bariatric surgery can achieve significant weight loss and improvement of liver function tests. However, there existed significant risk of HBV reactivation after bariatric surgery for patients with obesity.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Bariatric surgery; Hepatitis B virus; Non-alcoholic fatty liver disease; Viral load

Mesh:

Substances:

Year:  2022        PMID: 35922612     DOI: 10.1007/s11695-022-05979-0

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   3.479


  1 in total

1.  MiR-196a promotes the proliferation and migration of esophageal cancer via the UHRF2/TET2 axis.

Authors:  Chang-Mei Hu; Jie Peng; Liang Lv; Xue-Hong Wang; Ji-Rong Huo; De-Liang Liu
Journal:  Mol Cell Biochem       Date:  2021-11-26       Impact factor: 3.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.